Concept
Intron
Related people (13)
Bernard Moret
Bernard M.E. Moret was born in Vevey, Switzerland, received baccalauréats in Latin-Greek and Latin-Mathematics, then did a Diploma in Electrical Engineering at EPFL. After working for 2 years for Omega and Swiss Timing on the development of real-time OS for sports applications, he left for the US. He received his PhD in Electrical Engineering from the U. of Tennessee in 1980 and joined the Department of Computer Science at the University of New Mexico (UNM) that fall. He served as Chairman of the department from 1991 till 1993 and eventually retired in summer 2006 to join the School of Computer and Communication Sciences at EPFL. (You can read about his work at UNM on his (archived) personal and laboratory web pages at UNM.) He was appointed group leader for phylogenetics at the Swiss Institute for Bioinformatics (SIB). From 2009 until his retirement, he was also in charge of the BS and MS programs in Computer Science and Associate Dean for Education. He founded the ACM Journal of Experimental Algorithmics (JEA) and served as its Editor-in-Chief for 7 years; he also helped found the IEEE/ACM Transactions on Computational Biology and Bioinformatics (TCBB), where he served as Associate Editor until 2008. He founded the annual Workshop on Algorithms in Bioinformatics (WABI) and chairs its steering committee, and he serves on the steering committee of the Workshop on Algorithm Engineering and Experiments (ALENEX). Until summer 2008, he chaired the Biodata Management and Analysis (BDMA) study section of the US National Institutes of Health (NIH); now he is a charter member of the NIH College of Reviewers. He led a team of over 50 biologists, computer scientists, and mathematicians in the CIPRES (Cyber Infrastructure for Phylogenetic Research) project, funded by the US National Science Foundation (NSF) for US$ 12 million over 5 years. He has published nearly 150 papers in computational biology, under funding from the US NSF, the Alfred P. Sloan foundation, the IBM Corporation, the US NIH, the Swiss NSF, and SystemsX.ch. He is a Fellow of the ISCB (International Society for Computational Biology). His Erdös number is 2 and (as of 2020) his h-index is 48.
Johan Auwerx
Johan Auwerx is Professor at the École Polytechnique Fédérale in Lausanne, Switzerland, where he occupies the Nestle Chair in Energy Metabolism. Dr. Auwerx has been using molecular physiology and systems genetics to understand metabolism in health, aging and disease. Much of his work focused on understanding how diet, exercise and hormones control metabolism through changing the expression of genes by altering the activity of transcription factors and their associated cofactors. His work was instrumental for the development of agonists of nuclear receptors - a particular class of transcription factors - into drugs, which now are used to treat high blood lipid levels, fatty liver, and type 2 diabetes. Dr. Auwerx was amongst the first to recognize that transcriptional cofactors, which fine-tune the activity of transcription factors, act as energy sensors/effectors that influence metabolic homeostasis. His research validated these cofactors as novel targets to treat metabolic diseases, and spurred the clinical use of natural compounds, such as resveratrol, as modulators of these cofactor pathways.
Johan Auwerx was elected as a member of EMBO in 2003 and is the recipient of a dozen of international scientific prizes, including the Danone International Nutrition Award, the Oskar Minkowski Prize, and the Morgagni Gold Medal. His work is highly cited by his peers with a h-factor of over 100. He is an editorial board member of several journals, including Cell Metabolism, Molecular Systems Biology, The EMBO Journal, Journal of Cell Biology, Cell, and Science. Dr. Auwerx co-founded a handful of biotech companies, including Carex, PhytoDia, and most recently Mitobridge, and has served on several scientific advisory boards.
Dr. Auwerx received both his MD and PhD in Molecular Endocrinology at the Katholieke Universiteit in Leuven, Belgium. He was a post-doctoral research fellow in the Departments of Medicine and Genetics of the University of Washington in Seattle.
Andrew Charles Oates
After an undergraduate degree in Biochemistry at the University of Adelaide with Honours in Robert Saint’s lab, Andrew Oates received his Ph.D. at the Ludwig Institute for Cancer Research and the University of Melbourne in the lab of Andrew Wilks. His postdoctoral time was at Princeton University and the University of Chicago in the lab of Robert Ho, where his studies on the segmentation clock in zebrafish began in 1998. In 2003 he moved to Germany and started his group at the Max Planck Institute for Molecular Cell Biology and Genetics in Dresden. In 2012 he accepted a position at University College London as Professor of vertebrate developmental genetics and moved his group to the MRC-National Institute for Medical Research at Mill Hill in London. From April 2015, he became a member of the Francis Crick Institute in London. In September 2016, he joined École polytechnique fédéral de Lausanne (EPFL) in Switzerland as a Professor, where he is the head of the Timing, Oscillation, Patterns Laboratory. From April 2018 he served as Director of the Institute of Bioengineering, and from January 2021 became the Dean of the School of Life Sciences.
The Timing, Oscillation, Patterns Laboratory is composed of biologists, engineers, and physicists using molecular genetics, quantitative imaging, and theoretical analysis to study a population of coupled genetic oscillators in the vertebrate embryo termed the segmentation clock. This system drives the rhythmic, sequential, and precise formation of embryonic body segments, exhibiting rich spatial and temporal phenomena spanning from molecular to tissue scales.
Stewart Cole
Professor Stewart Cole is an international authority in bacterial molecular-genetics and genomics. He has made outstanding contributions in several fields including: bacterial anaerobic electron transport; genome analysis of retroviruses and papillomaviruses; antibiotic resistance mechanisms; and the molecular microbiology of toxigenic clostridia. His studies on isoniazid and multidrug resistance in Mycobacterium tuberculosis, together with his pioneering work on the pathogenicity, evolution and genomics of the tubercle and leprosy bacilli, have made him an undisputed leader in the field of mycobacterial research. The findings of his research are of direct relevance to public health and disease-control in both the developing world and the industrialised nations. He has published over 250 scientific papers and review articles, and holds many patents.
Jacques Fellay
Jacques Fellay is a medical scientist with expertise in infectious diseases and human genomics. He obtained his MD from the University of Lausanne in 2002 and his PhD from University of Utrecht. After a clinical training in infectious diseases in Switzerland and a 4-years postdoctoral fellowship at Duke University, he joined the EPFL in April 2011 with an SNF Professorship.
On top of his EPFL affiliation, Jacques is also Head of Precision Medicine at the University Hospital (CHUV) in Lausanne, Group Leader at the Swiss Institute of Bioinformatics, and Co-director of the Health2030 Genome Center at Campus Biotech in Geneva.
Felix Naef
Felix Naef studied theoretical physics at the ETHZ and obtained his PhD from the EPFL in 2000. He then received postdoctoral training at the Center for Studies in Physics and Biology at the Rockefeller University (NYC) under the guidance of Prof. Magnasco. His research focuses on the modeling and interpretation of high-throughput functional data and the study of biomolecular oscillators. He joined ISREC as an associate scientist in early 2004 and is currently Associate Professor in the Institute of Bioengineering (IBI).
Denis Duboule
Denis Duboule is born in 1955 and is both swiss and french national. He studied biology at the university of Geneva, where he obtained a PhD in mammalian embryology in 1984. He then spent 10 years abroad, first as a group leader in the medical faculty in Strasbourg (France), then at the European Laboratory for Molecular Biology (EMBL) in Germany. In 1993, he was appointed full professor at the university of Geneva, where he chairs the department of Genetics and Evolution ever since 1997. In 2001, he chaired the national center of research Frontiers in Genetics and in 2012 the division III of the SNSF. In 2006, he was appointed full professor at the federal institute of technology (EPFL) in Lausanne, where he leads the laboratory of Developmental Genomics (UpDUB).
His research activities are in the fields of embryology, genetics and developmental genomics of mammals, in an evolutionnary context. In particular, his laboratory has been closely associated with the structural and functional studies of mammalian Hox genes, by using mouse molecular genetic approaches. Duboule is also active in the communication of science, is member of the Academia Europea as well as of several academies in Switzerland, France and the Netherland. He is a foreign member of the Royal Society (UK) and of the National Academy of Sciences USA. He has received various scientific prizes and awards, amongst which the Marcel Benoist Prize, the Louis-Jeantet prize for medicine in 1998 or the international INSERM prize in 2010 (see also https://en.wikipedia.org/wiki/Denis_Duboule).
Didier Trono
After obtaining an M.D. from the University of Geneva and completing a clinical training in pathology, internal medicine and infectious diseases in Geneva and at Massachusetts General Hospital in Boston, Didier Trono embarked in a scientific career at the Whitehead Institute for Biomedical Research of MIT. In 1990, he joined the faculty of the Salk Institute for Biological Studies to launch a center for AIDS research. He moved back to Europe seven years later, before taking the reins of the newly created EPFL School of Life Sciences, which he directed from 2004 to 2012. He is now actively engaged in the efforts of Switzerland to integrate new technologies in the fields of precision medicine and personalized health.